Delay to formalin fixation ‘cold ischemia time’: effect on ERBB2 detection by in-situ hybridization and immunohistochemistry
暂无分享,去创建一个
David L Rimm | Raymond R Tubbs | Erinn Downs-Kelly | D. Rimm | Deepa T. Patil | R. Tubbs | D. Hicks | G. Budd | E. Downs-Kelly | David G Hicks | B. Portier | Bryce P Portier | Zhen Wang | Jordi J Rowe | Deepa Patil | Chis Lanigan | G Thomas Budd | J. J. Rowe | Zhen Wang | Chis Lanigan | Jordi J Rowe | G. Budd | David G Hicks | David L Rimm | Raymond R Tubbs | E. Downs‐Kelly | David G. Hicks | Raymond R. Tubbs | G. T. Budd
[1] D. Hicks,et al. Breast cancer predictive factor testing: the challenges and importance of standardizing tissue handling. , 2011, Journal of the National Cancer Institute. Monographs.
[2] S. Edge,et al. HER2 Testing: How to Reach a High Concordance Rate Between Immunohistochemistry and Fluorescence In Situ Hybridization , 2011, Applied immunohistochemistry & molecular morphology : AIMM.
[3] T. Fleming,et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. , 2001, The New England journal of medicine.
[4] L. Layfield,et al. Effects of Fixative and Fixation Protocols on Assessment of Her-2/neu Oncogene Amplification Status by Fluorescence In Situ Hybridization , 2007, Applied immunohistochemistry & molecular morphology : AIMM.
[5] M. Millward,et al. Cost Effectiveness of Trastuzumab in the Adjuvant Treatment of Early Breast Cancer , 2012, PharmacoEconomics.
[6] Anthony Rhodes,et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. , 2007, Archives of pathology & laboratory medicine.
[7] G. Wilding,et al. Delay to formalin fixation effect on breast biomarkers , 2009, Modern Pathology.
[8] Thomas J. Smith,et al. Do the large benefits justify the large costs of adjuvant breast cancer trastuzumab? , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] G. Barosi,et al. Cost effectiveness of adjuvant trastuzumab in human epidermal growth factor receptor 2-positive breast cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] N. Moatamed,et al. The effect of delay in fixation, different fixatives, and duration of fixation in estrogen and progesterone receptor results in breast carcinoma. , 2011, American journal of clinical pathology.
[11] P. Tan,et al. Effect of Fixation Period on HER2/neu Gene Amplification Detected by Fluorescence In Situ Hybridization in Invasive Breast Carcinoma , 2002, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.
[12] A. Gown,et al. Fixation time does not affect expression of HER2/neu. , 2011, American journal of clinical pathology.
[13] E. Winer,et al. Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trial. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] C. Stewart,et al. Discrepancy in ER levels of breast carcinoma in biopsy vs mastectomy specimens , 1985, Journal of surgical oncology.
[15] David Y. Lu,et al. Effect of ischemic time, fixation time, and fixative type on HER2/neu immunohistochemical and fluorescence in situ hybridization results in breast cancer. , 2011, American journal of clinical pathology.
[16] L. Rogers,et al. Fixation time does not affect expression of HER2/neu: a pilot study. , 2010, American journal of clinical pathology.
[17] Greg Yothers,et al. Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] A. Chaudhuri,et al. HER2 Status and Benefit from Adjuvant Trastuzumab in Breast Cancer , 2008 .
[19] L. Goldstein,et al. High concordance between immunohistochemistry and fluorescence in situ hybridization testing for HER2 status in breast cancer requires a normalized IHC scoring system , 2008, Modern Pathology.
[20] D. Dabbs,et al. Fixation time does not affect the expression of estrogen receptor. , 2011, American journal of clinical pathology.
[21] M. Sliwkowski,et al. Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers , 1999, Oncogene.
[22] R. Finn,et al. Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs , 1998, Oncogene.
[23] L. Norton,et al. Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts. , 1998, Cancer research.
[24] D. Lake,et al. The safety of dose-dense doxorubicin and cyclophosphamide followed by paclitaxel with trastuzumab in HER-2/neu overexpressed/amplified breast cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[25] A. Gown. Current issues in ER and HER2 testing by IHC in breast cancer , 2008, Modern Pathology.
[26] D. Arber. Effect of Prolonged Formalin Fixation on the Immunohistochemical Reactivity of Breast Markers , 2002, Applied immunohistochemistry & molecular morphology : AIMM.